Download the Full Event Guide for Full Session Details.

• VAV1 is a FIC target for autoimmune and chronic inflammatory diseases
• Hinova discovers novel VAV1 degrader with high potency and selectivity
• Achieved complete VAV1 degradation in vivo upon single oral dosing of VAV1 degrader